BioSpace News Archive

Translate Bio, a clinical-stage messenger RNA therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, reported that on March 22, 2021, the Company granted non-qualified stock options to purchase an aggregate of 300,000 shares of the Company’s common stock to its newly hired President, Dr. Rand Sutherland.

Tallac Will Draw on Selexis’ Best-in-Class Cell Line Development Technologies Under New Commercial License and Service Agreements

SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, genetically defined neurological conditions, today announced that Marita James, CPA, has been appointed as the company’s Chief Financial Officer.

CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has secured an extension to its Schedule I U.S. Drug Enforcement Agency (DEA) license that will allow the Company to conduct research on psychedelics-based pharmaceuticals

FDA-cleared Concussion Index is the only brain activity-based biomarker for rapid, objective baselining and assessment of concussion at injury and recovery time points

Abveris, Inc. today announced the release of antibody sequences specific to the SARS-CoV-2 spike (S) protein into the public domain for unrestricted use. Leveraging Alloy Therapeutic’s ATX-Gx™ human transgenic mouse platform in parallel with genetically engineered DiversimAb™ mice,

Data analysis from earlier COVI-GAPP pilot study shows Ava’s algorithm accurately detected 71% of COVID-19 positive infections two days prior to symptom onset

Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has received a total of $2,054,000 to date from the recently announced committed minimum financing of $2,000,000 with RB Capital Partners Inc.

SiteOne Therapeutics Inc., a private biopharmaceutical company developing new treatments to address conditions involving hypersensitivity of the nervous system, today announced the appointment of John Mulcahy, Ph.D., as chief executive officer

New programs, designed in partnership with iDesign, will soon enable access to online courses from Michigan’s School of Social Work and Medical School, helping meet growing workforce demand in social work and learning health sciences